Ara
Toplam kayıt 5, listelenen: 1-5
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
(Wiley, 2023)
The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese.
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply
(Wiley, 2023)
We appreciate the editorial comments by Drs. Sun and Fan about our study assessing the associations of patient-reported outcomes (PROs) and non-invasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) ...
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
(Kare Publishing, 2023)
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
The heated debate over NAFLD renaming: An ongoing saga
(Kare Publishing, 2023)
In 1980, Jurgen Ludwig, a pathologist at the Mayo Clinic, and colleagues formally described a disorder that involved the accumulation
of fat in the liver, independent of significant alcohol consumption, or
other secondary ...
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
(Kare Publishing, 2024)
The term metabolic dysfunction-associated steatotic liver disease
(MASLD), which evolved from its predecessor, nonalcoholic fatty liver
disease (NAFLD),[1]